NO308580B1 - Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin - Google Patents

Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin

Info

Publication number
NO308580B1
NO308580B1 NO953961A NO953961A NO308580B1 NO 308580 B1 NO308580 B1 NO 308580B1 NO 953961 A NO953961 A NO 953961A NO 953961 A NO953961 A NO 953961A NO 308580 B1 NO308580 B1 NO 308580B1
Authority
NO
Norway
Prior art keywords
hypertriglyceridemic
drug
preparation
cyclic compounds
condensed cyclic
Prior art date
Application number
NO953961A
Other languages
English (en)
Other versions
NO953961D0 (no
NO953961L (no
Inventor
Yasuo Sugiyama
Hidefumi Yukimasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO953961D0 publication Critical patent/NO953961D0/no
Publication of NO953961L publication Critical patent/NO953961L/no
Publication of NO308580B1 publication Critical patent/NO308580B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO953961A 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin NO308580B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07

Publications (3)

Publication Number Publication Date
NO953961D0 NO953961D0 (no) 1995-10-05
NO953961L NO953961L (no) 1996-04-09
NO308580B1 true NO308580B1 (no) 2000-10-02

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953961A NO308580B1 (no) 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin

Country Status (11)

Country Link
EP (1) EP0705607A2 (no)
KR (1) KR960013370A (no)
CN (1) CN1128657A (no)
AU (1) AU703422B2 (no)
CA (1) CA2160092A1 (no)
FI (1) FI954773A (no)
HU (1) HUT73422A (no)
NO (1) NO308580B1 (no)
NZ (1) NZ280165A (no)
RU (1) RU2166320C2 (no)
TW (1) TW401301B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231052C (en) * 1995-09-13 2007-11-13 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP0843559A2 (en) * 1996-06-11 1998-05-27 Zonagen, Inc. Chitosan drug delivery system
ATE309993T1 (de) 1997-04-21 2005-12-15 Takeda Pharmaceutical 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU5588400A (en) 1999-05-26 2000-12-18 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
JP2003506440A (ja) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 中枢神経系に関連する疾患の処置のための１，４−ジアゼピン誘導体
WO2002038180A1 (fr) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. Agent haute densite faisant monter le taux de lipoproteine-cholesterol
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
EP1591120A4 (en) * 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006016681A2 (en) * 2004-08-09 2006-02-16 Takeda Pharmaceutical Company Limited Crp lowering agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
KR20100017766A (ko) 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤조-1,4-디아제핀 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 이의 용도
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN115916754A (zh) 2020-05-05 2023-04-04 纽威伦特公司 杂芳族大环醚化学治疗剂
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567026B1 (en) * 1992-04-20 2003-03-26 Takeda Chemical Industries, Ltd. 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU1589895A (en) * 1994-02-09 1995-08-29 Takeda Chemical Industries Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
NO953961D0 (no) 1995-10-05
CA2160092A1 (en) 1996-04-08
HUT73422A (en) 1996-07-29
HU9502918D0 (en) 1995-11-28
FI954773A (fi) 1996-04-08
KR960013370A (ko) 1996-05-22
RU2166320C2 (ru) 2001-05-10
FI954773A0 (fi) 1995-10-06
EP0705607A2 (en) 1996-04-10
CN1128657A (zh) 1996-08-14
NO953961L (no) 1996-04-09
AU3308195A (en) 1996-04-18
NZ280165A (en) 1997-07-27
TW401301B (en) 2000-08-11
EP0705607A3 (no) 1996-05-08
AU703422B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
NO308580B1 (no) Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin
NO900830L (no) Fremgangsmaate for fremstilling av piperidinforbindelser.
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
NO912411D0 (no) Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser.
NO910395D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 4-isoxazolcarboxamidderivater.
NO905008D0 (no) Fremgangsmaate for fremstilling av heterocykliske forbindelser.
NO900774D0 (no) Fremgangsmaate for fremstilling av polyamider.
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
FI940697A0 (fi) Kondensoidut 5-jäseniset heterosyklit, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät lääkeaineet
NO924632D0 (no) Fremgangsmaate for fremstilling av cykliske sulfater
NO930574L (no) Fremgangsmaate for fremstilling av desfluran
FI935654A (fi) Kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
NO994083D0 (no) Selektiv epoksideringsmetode for fremstilling av farmasöytiske forbindelser
NO955082L (no) Fremgangsmåte for fremstilling av glutardialdehyd
NO306065B1 (no) Fremgangsmåte for fremstilling av organoklorsilaner
NO913692D0 (no) Fremgangsmaate for fremstilling av karbapenemforbindelser.
NO892432D0 (no) Fremgangsmaate for fremstilling av kondenserte diazepinoner
NO910186L (no) Fremgangsmaate for fremstilling av et oralt inhalerbart, farmasoeytisk atropin-salbutamol-aerosolpreparat.
NO961008D0 (no) Fremgangsmåte for fremstilling av cykliske cis-1-amino-2-alkanoler
NO904535D0 (no) Fremgangsmaate for fremstilling av fenoxy-heterocykliske forbindelser.
FI924881A (fi) Foerfarande foer framstaellning av (2R, 3E)-4-halo-3-buten-2-oler
NO903397D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av protocatechualdehyd.
NO924763L (no) Ny fremgangsmaate for fremstilling av 4-amino-5-hexensyre
FI972694A0 (fi) Uusi menetelmä sameridiinin valmistamiseksi
FI961717A0 (fi) Menetelmä oraalisten, kinoloneja sisältävien valmisteiden valmistamiseksi

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003